Clinical policy: Critical issues in the initial evaluation and management of patients presenting to the emergency department in early pregnancy

Annals of Emergency Medicine

Volumn 41, Issue 1, 2003, Pages 123-133

  Murphy, Barbara A ^a   Hansen, Alfred R ^a   Howell, John M ^a   Simmons, Bonnie ^a   Cantrill, Stephen V ^a   Dalsey, William C ^a   Jagoda, Andy S ^a   Colucciello, Stephen A ^a   Decker, Wyatt W ^a   Fesmire, Francis M ^a   Godwin, Steven A ^a   Huff, J Stephen ^a   Itzkowitz, Alan H ^a   Karas Jr , Stephen ^a   Kuffner, Edwin K ^a   Lukens, Thomas W ^a   Marett, Benjamin E ^a   Martin, Thomas P ^a   Moore, Jessie ^a   Morgan, David L ^a   Nazarian, Devorah ^a   Silvers, Scott M ^a   Sloan, Edward P ^a   Wall, Suzanne ^a   Wears, Robert L ^a   Wolf, Stephen J ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CHORIONIC GONADOTROPIN; DIHYDROFOLATE REDUCTASE; FOLIC ACID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RHESUS ANTIGEN; RHESUS D ANTIBODY;

ABDOMINAL CRAMP; ABDOMINAL INJURY; ABORTION; BLOOD GROUP RHESUS SYSTEM; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CURETTAGE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG MECHANISM; DRUG SAFETY; ECTOPIC PREGNANCY; EMERGENCY TREATMENT; FEMALE; FIRST TRIMESTER PREGNANCY; GASTROINTESTINAL TOXICITY; GONADOTROPIN BLOOD LEVEL; HEALTH CARE POLICY; HEMOPERITONEUM; HUMAN; MEDICAL DECISION MAKING; MEDICAL SOCIETY; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHESUS IMMUNIZATION; RHESUS INCOMPATIBILITY; RISK FACTOR; STOMATITIS; TRANSVAGINAL ECHOGRAPHY; TREATMENT FAILURE; VOMITING;

EID: 0037228947     PISSN: 01960644     EISSN: None     Source Type: Journal    
DOI: 10.1067/mem.2003.13     Document Type: Review

References (66)

1. American College of Emergency Physicians. Clinical policy forthe initial approach to patients presenting with a chief complaint of vaginal bleeding. Ann Emerg Med. March 1997;29:435-458.
2. Centers for Disease Control and Prevention. Current trends in ectopic pregnancy-United States, 1990-1992. MMWR Morb Mortal Wkly Rep. 1995;44:46-48. [II]
3. Saraiya M, Berg CJ, Shulman H, et al. Estimates of the annual number of clinically recognized pregnancies in the United States, 1981-1991. Am J Epidemiol. 1999;149:1025-1029. [III]
4. Strathy J, Coulam C, Marchbanks P, et al. Incidence of ectopic pregnancy in Rochester Minnesota, 1950-1981. Obstet Gynecol. 1984;64:37-43. [II]
5. Makinen JL. Increase of ectopic pregnancy in Finland - combination of time and cohort effects. Obstet Gynecol. 1989;73:21,24. [II]
6. Makinen JL, Rantala M, Vanha-Kamppa O. A link between the epidemic of ectopic pregnancy and the "baby-boom" cohort. Am J Epidemiol. 1998;148:369-374. [II]
7. Ankum W, Mol B, Van der Veen F, et al. Risk factors for ectopic pregnancy: a meta-analysis. Fertil Steril. 1996;65:1093-1099. [II]
8. Skieldestad FE, Hadgu A, Eriksson N. Epidemiology of repeat ectopic pregnancy: a population-based prospective cohort study. Obstet Gynecol. 1998;91:129-135. [II]
9. Pisarska MD, Carson SA, Buster JE. Ectopic pregnancy. Lancet. 1998;351:1115-1120. [III]
10. Pisarska MD, Carson SA. Incidence and risk factors for ectopic pregnancy. Clin Obstet Gynecol. 1999;42:2-8. [III]
11. Marcus S, Brinsden P. Analysis of the incidence and risk factors associated with ectopic pregnancy following in-vitro fertilization and embryo transfer. Hum Reprod. 1995;10:199-203. [II]
12. Strandell A, Thorburn J, Hamberger L. Risk factors for ectopic pregnancy in assisted reproduction. Fertil Steril. 1999;71:282-286. [II]
13. Dubuisson J, Aubriot F, Mathieu L, et al. Risk factors for ectopic pregnancy in 556 pregnancies after in vitro fertilization: implications for preventive management. Fertil Steril. 1991;45:686-690. [II]
14. Pyrgiotis E, Silton K, Neal G, et al. Ectopic pregnancies after in vitro fertilization and embryo transfer. J Assisted Reprod Genet. 1994;11:79-84. [II]
15. Rojansky N, Schenker JG. Heterotopic pregnancy and assisted reproduction - an update. J Assist Reprod Genet. 1996;13:594-601. [III]
16. Schriger DL, Cantrill SV, Greene CS. The origins, benefits, harms and implications of emergency medicine clinical policies. Ann Emerg Med. 1993;22:597-602. [III]
17. Bernaschek GR, Rudelstorfer R, Csaicsich P. Vaginal sonography versus serum human chorionic gonadotropin in early detection of pregnancy. Am J Obstet Gynecol. 1988;158:608-612. [II]
18. Kadar NM, Bohrer M, Kemmann E, et al. The discriminatory human chorionic gonadotropin zone for endovaginal sonography: a prospective, randomized study. Fertil Steril. 1994;61:1016-1020. [II].
19. Nyberg DA, Mack LA, Laing FC, et al. Early pregnancy complications: endovaginal sonographic findings correlated with human chorionic gonadotropin levels. Radiology. 1988;167:619-622. [II]
20. Shapiro BS, Escobar M, Makruch R, et al. A model-based prediction for transvaginal ultrasonographic identification of early intrauterine pregnancy. Am J Obstet Gynecol. 1992;166:1495-1500. [II]
21. Kaplan BC, Dart RG, Moskos M, et al Ectopic pregnancy: prospective study with improved diagnostic accuracy. Ann Emerg Med. 1996;28:10-17. [I]
22. Dart RG, Kaplan B, Cox C. Transvaginal ultrasound in patients with low β-human chorionic gonadotropin values: how often is the study diagnostic? Ann Emerg Med. 1997;30:135-140. [II]
23. Mol BWJ, Haienius PJ, Engelsbel S, et al. Serum human chorionic gonadotropin measurement in the diagnosis of ectopic pregnancy when transvaginal ultrasound is inconclusive. Fertil Steril. 1998;70:972-981. [II]
24. Shepherd RW, Patton QI, Novy MJ, et al. Serial beta-hCG measurements in the early detection of ectopic pregnancy. Obstet Gynecol. 1990;75:417-420. [II]
25. Romero R, Kadar N, Copel J, et al. The value of serial human chorionic gonadotropin testing as a diagnostic tool in ectopic pregnancy. Am J Obstet Gynecol. 1986;155:392-394. [III]
26. Kadar NG, Caldwell BV, Romero R. A method of screening for ectopic pregnancy and its indications. Obstet Gynecol. 1981;58:162-165. [III]
27. Goldstein SR, Snyder JR, Watson C, et al. Very early pregnancy detection with endovaginal ultrasound. Obstet Gynecol. 1988;72:200-204. [II]
28. Stitka CS, Anderson L, Fredericksen MC. Single dose methotrexate for the treatment of ectopic pregnancy: Northwestern Memorial Hospital three-year experience. Am J Obstet Gynecol. 1996;174:1846-1848. [II]
29. Jimenez-Caballo A, Rodriguez-Donoso G. A 6-year clinical trial of methotrexate therapy in the treatment of ectopic pregnancy. Eur J Obstet Gynecol. Reprod Biol. 1998;79:167-171. [II]
30. Haienius PJ, Engelsbel S, Mol BWJ, et al. Randomized trial of systemic methotrexate versus laparoscopic salpingostomy in tubal pregnancy. Lancet. 1997;350:771-779. [II]
31. American College of Obstetricians and Gynecologists. Medical management of tubal pregnancy ACOG Practice Bulletin 3. Washington, DC: ACOG;1998. [III]
32. Stovall TG, Ling FW. Single-dose methotrexate: an expanded clinical trial. Am J Obstet Gynecol. 1993;168:1759-1765. [I]
33. Fernandez H, Bourget P, Ville Y, et al. Treatment of unruptured tubal pregnancy with methotrexate: pharmokinetic analysis of local versus intramuscular administration. Fertil Steril. 1994;62:943-947. [II]
34. Fernandez H, Capella-Allouc YVS, Pauthier S, et al. Randomized trial of conservative laparoscopic treatment and methotrexate administration in ectopic pregnancy and subsequent fertility. Hum Reprod. 1998;13:3239-3243. [I]
35. Yao M, Tulandi T, Falcone T. Treatment of ectopic pregnancy by systemic methotrexate, transvaginal methotrexate and operative laparoscopy. Int J Fertil. 1996;41:470-475. [II]
36. Korhonen J, Stenman UH, Ylostalo O. Low-dose oral methotrexate with expectant management of ectopic pregnancy. Obstet Gynecol. 1996;88:775-778. [I]
37. Lipscomb GH, Bran D, McCord ML, et al. Analysis of three hundred fifteen ectopic pregnancies treated with single-dose methotrexate. Am J Obstet Gynecol. 1998;178:1354-1358. [I]
38. Gross Z, Rodriguez J, Stalnaker BL. Ectopic pregnancy. Nonsurgical, outpatient evaluation and single-dose methotrexate treatment. J Reprod Med. 1995;40:371-374. [II]
39. Pietrzak Z, Augustyniak T, Szram K, et al. Efficacy of methotrexate in the treatment of nonruptured ectopic pregnancy. Acta Obstet Gynecol. Scand. 1999;78:258-259. [II]
40. Thoen LD, Creinin MD. Medical treatment of ectopic pregnancy with methotrexate. Fertil Steril. 1997;68:727-730. [I]
41. Lipscomb GH, McCord ML, Stovall TG, et al. Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies. N Engl J Med. 1999;341:1974-1978. [II]
42. Hung TH, Shau WY, Hsieh TT, et al. Prognostic factors for an unsatisfactory primary methotrexate treatment of cervical pregnancy: a quantitative review. Hum Reprod. 1998;13:2636-2642. [II]
43. Bergstrom H, Nilsson LA, Nilsson L, et al. Demonstration of Rh antigens in a 38 day old fetus. Am J Obstet Gynecol. 1967;99:130-133. [III]
44. Urbaniak SJ. The scientific basis of antenatal prophylaxis. Br J Obstet Gynaecol. 1998;105:11-18. [III]
45. Hartwell EA. Use of Rh immune globulin. Am J Clin Path. 1998;110:281-292. [III]
46. Cohen F, Gustafson PC, Evans NM. Mechanisms of isoimmunization; the transplacental passage of fetal erythrocytes in homospecific pregnancies. Blood. 1964;23:621 [II]
47. Stern K, Goodman HS, Berger M. Experimental iso-immunization to hemo antigens in man. J Immunol. 1961;87:189-198. [I]
48. Jakobovicz R, Williams L, Silberman D. Immunization of Rh negative volunteers with repeated injection of very small amounts of Rh positive blood. Vox Sang. 1972;23:376-381. [III]
49. Contreras M. The prevention of Rh haemolytic disease of the fetus and newborn - general background. Brit J ObstetGynaecol. 1998;105:7-10. [III]
50. Bowman J. The prevention of Rh immunization. Transfus Med Rev. 1998;2:129-150. [III]
51. Katz J, Marcus RG. The risk of isoimmunization in ruptured tubal pregnancy. BMJ. 1972;3:667-669. [II]
52. Litwak O, Taswell HF, Banner EA, et al. Fetal erythrocytes in maternal circulation after spontaneous abortion. JAMA. 1970;214:531-534. [II]
53. Stewart FH, Burnhill MS, Bozorgi N. Reduced dose of Rh immunoglobulin following first trimester pregnancy termination. Obstet Gynecol. 1978;51:318-322. [II]
54. Rose PG, Strohm PL, Zuspan FP. Fetomaternal hemorrhage following trauma. Am J Obstet Gynecol. 1985;153:844-847. [II]
55. Hughes RG, Craig JIO, Murphy WG, et al. Causes and clinical consequences of Rhesus D haemolytic disease of newborn: a study of a Scottish population, 1985-1990. Br J Obstet Gynaecol. 1994;101:297-300. [III]
56. McSweeney E, Kirkham J, Vinall P, et al. An audit of anti-D sensitization in Yorkshire. Br J Obstet Gynaecol. 1998;105:1091-1094. [III]
57. Chown B, Duff AM, James J, et al. Prevention of primary Rh immunization. First report of the western Canadian trial. Can Med Assoc J. 1969;100:1021-1024. [III]
58. Prevention of Rh-haemolytic disease: results of the clinical trial. A combined study from centres in England and Baltimore. BMJ. 1966;2:907-914. [II]
59. Ghosh S, Murphy WG. Implementation of the rhesus prevention program: a prospective study. Scott Med J. 1994;39:147-149. [III]
60. Thornton JG, Page C, Foote G, et al. Efficacy and long term effects of antenatal prophylaxis with anti-D immunoglobulin. BMJ. 1989;298:1671-1673. [II]
61. American College of Obstetricians and Gynecologists. Prevention of Rh D alloimmunization. ACOG Practice Bulletin 4. Washington, DC: ACOG;1999. [III]
62. Bowman JM. Controversies in Rh prophylaxis: who needs Rh immune globulin and when should it be given? Am J Obstet Gynecol. 1985;151:289-294. [III]
63. Bowman JM, Pollock JM, Penston LE. Fetomaternal transplacental hemorrhage during pregnancy and after delivery. Vox Sang. 1986;51:117-121. [II]
64. Von Stein GA, Munsick RA, Stiver K, et al. Fetomaternal hemorrhage in threatened abortion. Obstet Gynecol. 1992;79:383-386. [II]
65. Robson SC, Lee D, Urbaniak S. Anti-D immunoglobulin in RhD prophylaxis. BrJ Obstet Gynaecol. 1998;105:129-134. [III]
66. Aborjaily AN. Rh sensitization after tubal pregnancy. N Engl J Med. 1969;281:1076. [III]